Nine months into 2024, the search for effective neurodegenerative disease therapies continues, yielding a mix of promising advances and frustrating setbacks. After something of a lull in the 1990s and early 2000s, research into novel treatments for neurodegenerative diseases has surged back to life. One factor propelling the trend is the uptick in neurodegenerative disease…
Bayer moves forward with cell and gene therapies for Parkinson’s disease
Bayer announced today that its BlueRock Therapeutics subsidiary successfully administered the first dose of its Parkinson’s disease therapies. Berlin-based Bayer said in a news release that BlueRock successfully administered the dose of its investigational pluripotent stem cell-derived dopaminergic neruons, called DA01, to a Parkinson’s disease patient in an open-label Phase 1 clinical safety and tolerability…
What is needed to develop disease-modifying therapies for Parkinson’s and Alzheimer’s
Developing disease-modifying therapies for neurodegenerative diseases remains a pressing need. The incidence of neurodegenerative disease is ramping up in the U.S. and elsewhere as much of the global population ages. One out of three seniors dies with Alzheimer’s disease or another form of dementia, according to the Alzheimer’s Association. Parkinson’s disease is also becoming more…